<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00867165</url>
  </required_header>
  <id_info>
    <org_study_id>P05522</org_study_id>
    <secondary_id>2008-006271-70</secondary_id>
    <secondary_id>MK-0653-170</secondary_id>
    <nct_id>NCT00867165</nct_id>
  </id_info>
  <brief_title>Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522)</brief_title>
  <official_title>A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Efficacy and Safety Study of Ezetimibe Monotherapy in Children (Ages 6 to 10 Years) With Primary Hypercholesterolemia (Heterozygous Familial and Nonfamilial) (Phase 3, Protocol No. P05522)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of ezetimibe 10 mg/day compared to
      placebo on the reduction of low-density lipoprotein cholesterol (LDL-C) from baseline to 12
      weeks of treatment in children &gt;=6 to &lt;=10 years old with primary hypercholesterolemia. The
      study will also evaluate the effect of ezetimibe on total cholesterol (TC), apolipoprotein B
      (Apo B), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and triglycerides (TG). The
      safety of ezetimibe in this subject population will also be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 21, 2009</start_date>
  <completion_date type="Actual">April 13, 2012</completion_date>
  <primary_completion_date type="Actual">April 13, 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Serum LDL-C levels calculated at baseline and after 12 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) - (High-density lipoprotein cholesterol [HDL-C] + triglyceride [TG]/5).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Total Cholesterol (TC) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Serum TC levels measured using enzymatic methods at baseline and after 12 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Apolipoprotein B (Apo B) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Serum Apo B measured at baseline and after 12 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline High-density Lipoprotein Cholesterol (HDL-C) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Serum HDL-C levels measured by photometry after precipitation at baseline and after 12 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Non-HDL-C at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Serum Non-HDL-C calculated at baseline and after 12 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC - HDL-C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Triglycerides (TG) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Serum TG levels measured using enzymatic methods at baseline and after 12 weeks of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in LDL-C at Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>Serum LDL-C levels calculated at baseline and after 2 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) - (High-density lipoprotein cholesterol [HDL-C] + triglyceride [TG]/5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in LDL-C at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Serum LDL-C levels calculated at baseline and after 4 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) - (High-density lipoprotein cholesterol [HDL-C] + triglyceride [TG]/5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in LDL-C at Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Serum LDL-C levels calculated at baseline and after 8 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) - (High-density lipoprotein cholesterol [HDL-C] + triglyceride [TG]/5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in TC at Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>Serum TC levels measured using enzymatic methods at baseline and after 2 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in TC at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Serum TC levels measured using enzymatic methods at baseline and after 4 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in TC at Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Serum TC levels measured using enzymatic methods at baseline and after 8 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline HDL-C at Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>Serum HDL-C levels measured by photometry after precipitation at baseline and after 2 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline HDL-C at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Serum HDL-C levels measured by photometry after precipitation at baseline and after 4 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline HDL-C at Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Serum HDL-C levels measured by photometry after precipitation at baseline and after 8 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Non-HDL-C at Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>Serum Non-HDL-C calculated at baseline and after 2 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC - HDL-C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Non-HDL-C at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Serum Non-HDL-C calculated at baseline and after 4 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC - HDL-C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Non-HDL-C at Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Serum Non-HDL-C calculated at baseline and after 8 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC - HDL-C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in TG at Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>Serum TG levels measured using enzymatic methods at baseline and after 2 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in TG at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Serum TG levels measured using enzymatic methods at baseline and after 4 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in TG at Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Serum TG levels measured using enzymatic methods at baseline and after 8 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Apolipoprotein A-I (Apo A-I) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Serum Apo A-I levels measured at baseline and after 12 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in TC:HDL-C Ratio at Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>Serum TC:HDL-C Ratio calculated at baseline and after 2 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in TC:HDL-C Ratio at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Serum TC:HDL-C Ratio calculated at baseline and after 4 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in TC:HDL-C Ratio at Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Serum TC:HDL-C Ratio calculated at baseline and after 8 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in TC:HDL-C Ratio at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Serum TC:HDL-C Ratio calculated at baseline and after 12 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>Serum LDL-C:HDL-C Ratio calculated at baseline and after 2 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Serum LDL-C:HDL-C Ratio calculated at baseline and after 4 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Serum LDL-C:HDL-C Ratio calculated at baseline and after 8 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Serum LDL-C:HDL-C Ratio calculated at baseline and after 12 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Apo B:Apo A-I Ratio at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Serum Apo B:Apo A-I Ratio calculated at baseline and after 12 weeks of study drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Plasma hs-CRP measured at baseline and after 4 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Plasma hs-CRP measured at baseline and after 12 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Sitosterol at Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>Plasma sitosterol measured at baseline and after 2 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Sitosterol at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Plasma sitosterol measured at baseline and after 4 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Sitosterol at Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Plasma sitosterol measured at baseline and after 8 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Sitosterol at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Plasma sitosterol measured at baseline and after 12 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Campesterol at Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>Plasma campesterol measured at baseline and after 2 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Campesterol at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Plasma campesterol measured at baseline and after 4 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Campesterol at Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Plasma campesterol measured at baseline and after 8 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Campesterol at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Plasma campesterol measured at baseline and after 12 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Cholestanol at Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>Plasma cholestanol measured at baseline and after 2 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Cholestanol at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Plasma cholestanol measured at baseline and after 4 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Cholestanol at Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Plasma cholestanol measured at baseline and after 8 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Cholestanol at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Plasma cholestanol measured at baseline and after 12 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Lathosterol at Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>Plasma lathosterol measured at baseline and after 2 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Lathosterol at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Plasma lathosterol measured at baseline and after 4 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Lathosterol at Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Plasma lathosterol measured at baseline and after 8 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Lathosterol at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Plasma lathosterol measured at baseline and after 12 weeks of study drug administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Primary Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Ezetimibe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe</intervention_name>
    <description>oral tablets: ezetimibe 10 mg once daily for 12 weeks</description>
    <arm_group_label>Ezetimibe</arm_group_label>
    <other_name>SCH 58235</other_name>
    <other_name>MK-0653</other_name>
    <other_name>Zetia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral tablets: placebo to match ezetimibe 10 mg; administered once daily during the 5-week, single-blind, placebo run-in and diet stabilization period and 12-week double-blind treatment period</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Each subject may be of either sex and of any race/ethnicity, and must be &gt;=6 and &lt;=10
             years of age, with a diagnosis of primary hypercholesterolemia (heterozygous familial
             or nonfamilial) despite being on a lipid-lowering diet for at least 3 months with a
             LDL-C of &gt;159mg/dL

          -  Each subject's parent/guardian must be willing to give written informed consent on
             his/her behalf.

        Exclusion Criteria:

        Each subject must not:

          -  Have known hypersensitivity or any contraindication to ezetimibe.

          -  Have use of any investigational drugs within 30 days of study entry.

          -  Be a member or a family member of the personnel of the investigational or sponsor
             staff directly involved with this trial.

          -  Be a female of child-bearing potential who is pregnant, intends to become pregnant, or
             is nursing

          -  Have known congenital cardiac disorder.

          -  Have documented or laboratory values consistent with homozygous familial
             hypercholesterolemia (HoFH).

          -  Be known to be human immunodeficiency virus (HIV) positive.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Canada</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Kusters DM, Caceres M, Coll M, Cuffie C, Gagné C, Jacobson MS, Kwiterovich PO, Lee R, Lowe RS, Massaad R, McCrindle BW, Musliner TA, Triscari J, Kastelein JJ. Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia. J Pediatr. 2015 Jun;166(6):1377-84.e1-3. doi: 10.1016/j.jpeds.2015.02.043. Epub 2015 Apr 1.</citation>
    <PMID>25841542</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2009</study_first_submitted>
  <study_first_submitted_qc>March 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2009</study_first_posted>
  <results_first_submitted>April 10, 2013</results_first_submitted>
  <results_first_submitted_qc>April 10, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 30, 2013</results_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heterozygous familial hypercholesterolemia</keyword>
  <keyword>nonfamilial hypercholesterolemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ezetimibe</title>
          <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ezetimibe</title>
          <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="93"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="138"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.2" spread="1.7"/>
                    <measurement group_id="B2" value="8.5" spread="1.6"/>
                    <measurement group_id="B3" value="8.3" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12</title>
        <description>Serum LDL-C levels calculated at baseline and after 12 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) – (High-density lipoprotein cholesterol [HDL-C] + triglyceride [TG]/5).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study
medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12</title>
          <description>Serum LDL-C levels calculated at baseline and after 12 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) – (High-density lipoprotein cholesterol [HDL-C] + triglyceride [TG]/5).</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study
medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.70" lower_limit="-30.80" upper_limit="-24.59"/>
                    <measurement group_id="O2" value="-0.95" lower_limit="-4.94" upper_limit="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-26.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.80</ci_lower_limit>
            <ci_upper_limit>-22.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Total Cholesterol (TC) at Week 12</title>
        <description>Serum TC levels measured using enzymatic methods at baseline and after 12 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study
medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Total Cholesterol (TC) at Week 12</title>
          <description>Serum TC levels measured using enzymatic methods at baseline and after 12 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study
medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.74" lower_limit="-23.29" upper_limit="-18.18"/>
                    <measurement group_id="O2" value="0.19" lower_limit="-3.07" upper_limit="3.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-20.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.20</ci_lower_limit>
            <ci_upper_limit>-17.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Apolipoprotein B (Apo B) at Week 12</title>
        <description>Serum Apo B measured at baseline and after 12 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Apolipoprotein B (Apo B) at Week 12</title>
          <description>Serum Apo B measured at baseline and after 12 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.66" lower_limit="-24.94" upper_limit="-18.38"/>
                    <measurement group_id="O2" value="-1.42" lower_limit="-5.55" upper_limit="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-20.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.02</ci_lower_limit>
            <ci_upper_limit>-16.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline High-density Lipoprotein Cholesterol (HDL-C) at Week 12</title>
        <description>Serum HDL-C levels measured by photometry after precipitation at baseline and after 12 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline High-density Lipoprotein Cholesterol (HDL-C) at Week 12</title>
          <description>Serum HDL-C levels measured by photometry after precipitation at baseline and after 12 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" lower_limit="-2.27" upper_limit="6.48"/>
                    <measurement group_id="O2" value="1.41" lower_limit="-4.14" upper_limit="6.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.807</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.97</ci_lower_limit>
            <ci_upper_limit>6.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Non-HDL-C at Week 12</title>
        <description>Serum Non-HDL-C calculated at baseline and after 12 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC – HDL-C.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Non-HDL-C at Week 12</title>
          <description>Serum Non-HDL-C calculated at baseline and after 12 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC – HDL-C.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.47" lower_limit="-28.45" upper_limit="-22.49"/>
                    <measurement group_id="O2" value="0.28" lower_limit="-3.52" upper_limit="4.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Differrence in least-squares means</param_type>
            <param_value>-25.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.59</ci_lower_limit>
            <ci_upper_limit>-21.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Triglycerides (TG) at Week 12</title>
        <description>Serum TG levels measured using enzymatic methods at baseline and after 12 weeks of study drug.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Triglycerides (TG) at Week 12</title>
          <description>Serum TG levels measured using enzymatic methods at baseline and after 12 weeks of study drug.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.23" lower_limit="-12.73" upper_limit="0.75"/>
                    <measurement group_id="O2" value="8.44" lower_limit="-2.03" upper_limit="20.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>-14.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.35</ci_lower_limit>
            <ci_upper_limit>-2.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in LDL-C at Week 2</title>
        <description>Serum LDL-C levels calculated at baseline and after 2 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) – (High-density lipoprotein cholesterol [HDL-C] + triglyceride [TG]/5).</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in LDL-C at Week 2</title>
          <description>Serum LDL-C levels calculated at baseline and after 2 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) – (High-density lipoprotein cholesterol [HDL-C] + triglyceride [TG]/5).</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.75" lower_limit="-27.80" upper_limit="-21.69"/>
                    <measurement group_id="O2" value="0.23" lower_limit="-3.74" upper_limit="4.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-24.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.95</ci_lower_limit>
            <ci_upper_limit>-20.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in LDL-C at Week 4</title>
        <description>Serum LDL-C levels calculated at baseline and after 4 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) – (High-density lipoprotein cholesterol [HDL-C] + triglyceride [TG]/5).</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in LDL-C at Week 4</title>
          <description>Serum LDL-C levels calculated at baseline and after 4 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) – (High-density lipoprotein cholesterol [HDL-C] + triglyceride [TG]/5).</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.93" lower_limit="-29.81" upper_limit="-24.05"/>
                    <measurement group_id="O2" value="-2.99" lower_limit="-6.66" upper_limit="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-square means</param_type>
            <param_value>-23.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.49</ci_lower_limit>
            <ci_upper_limit>-20.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in LDL-C at Week 8</title>
        <description>Serum LDL-C levels calculated at baseline and after 8 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) – (High-density lipoprotein cholesterol [HDL-C] + triglyceride [TG]/5).</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in LDL-C at Week 8</title>
          <description>Serum LDL-C levels calculated at baseline and after 8 weeks of study drug administration. LDL-C were calculated by the method of Friedewald equation, LDL-C = Total Cholesterol (TC) – (High-density lipoprotein cholesterol [HDL-C] + triglyceride [TG]/5).</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.22" lower_limit="-30.30" upper_limit="-24.15"/>
                    <measurement group_id="O2" value="0.49" lower_limit="-3.46" upper_limit="4.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-27.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.70</ci_lower_limit>
            <ci_upper_limit>-23.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in TC at Week 2</title>
        <description>Serum TC levels measured using enzymatic methods at baseline and after 2 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in TC at Week 2</title>
          <description>Serum TC levels measured using enzymatic methods at baseline and after 2 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.69" lower_limit="-21.21" upper_limit="-16.18"/>
                    <measurement group_id="O2" value="1.40" lower_limit="-1.83" upper_limit="4.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-20.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.30</ci_lower_limit>
            <ci_upper_limit>-16.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in TC at Week 4</title>
        <description>Serum TC levels measured using enzymatic methods at baseline and after 4 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in TC at Week 4</title>
          <description>Serum TC levels measured using enzymatic methods at baseline and after 4 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.57" lower_limit="-23.05" upper_limit="-18.08"/>
                    <measurement group_id="O2" value="-0.29" lower_limit="-3.45" upper_limit="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-20.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.39</ci_lower_limit>
            <ci_upper_limit>-17.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in TC at Week 8</title>
        <description>Serum TC levels measured using enzymatic methods at baseline and after 8 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in TC at Week 8</title>
          <description>Serum TC levels measured using enzymatic methods at baseline and after 8 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.84" lower_limit="-23.40" upper_limit="-18.27"/>
                    <measurement group_id="O2" value="0.54" lower_limit="-2.73" upper_limit="3.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-21.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.67</ci_lower_limit>
            <ci_upper_limit>-18.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline HDL-C at Week 2</title>
        <description>Serum HDL-C levels measured by photometry after precipitation at baseline and after 2 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline HDL-C at Week 2</title>
          <description>Serum HDL-C levels measured by photometry after precipitation at baseline and after 2 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" lower_limit="-4.28" upper_limit="4.30"/>
                    <measurement group_id="O2" value="0.96" lower_limit="-4.51" upper_limit="6.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.733</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.46</ci_lower_limit>
            <ci_upper_limit>4.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline HDL-C at Week 4</title>
        <description>Serum HDL-C levels measured by photometry after precipitation at baseline and after 4 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline HDL-C at Week 4</title>
          <description>Serum HDL-C levels measured by photometry after precipitation at baseline and after 4 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" lower_limit="-3.69" upper_limit="5.42"/>
                    <measurement group_id="O2" value="0.33" lower_limit="-5.54" upper_limit="6.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.863</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>0.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.59</ci_lower_limit>
            <ci_upper_limit>6.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline HDL-C at Week 8</title>
        <description>Serum HDL-C levels measured by photometry after precipitation at baseline and after 8 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline HDL-C at Week 8</title>
          <description>Serum HDL-C levels measured by photometry after precipitation at baseline and after 8 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" lower_limit="-2.95" upper_limit="5.77"/>
                    <measurement group_id="O2" value="-0.52" lower_limit="-6.04" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.501</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>1.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.71</ci_lower_limit>
            <ci_upper_limit>7.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Non-HDL-C at Week 2</title>
        <description>Serum Non-HDL-C calculated at baseline and after 2 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC – HDL-C.</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Non-HDL-C at Week 2</title>
          <description>Serum Non-HDL-C calculated at baseline and after 2 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC – HDL-C.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.54" lower_limit="-25.41" upper_limit="-19.67"/>
                    <measurement group_id="O2" value="1.64" lower_limit="-2.03" upper_limit="5.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-24.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.78</ci_lower_limit>
            <ci_upper_limit>-20.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Non-HDL-C at Week 4</title>
        <description>Serum Non-HDL-C calculated at baseline and after 4 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC – HDL-C.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Non-HDL-C at Week 4</title>
          <description>Serum Non-HDL-C calculated at baseline and after 4 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC – HDL-C.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.94" lower_limit="-27.75" upper_limit="-22.14"/>
                    <measurement group_id="O2" value="-0.33" lower_limit="-3.88" upper_limit="3.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-24.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.06</ci_lower_limit>
            <ci_upper_limit>-21.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Non-HDL-C at Week 8</title>
        <description>Serum Non-HDL-C calculated at baseline and after 8 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC – HDL-C.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Non-HDL-C at Week 8</title>
          <description>Serum Non-HDL-C calculated at baseline and after 8 weeks of study drug administration. Non-HDL-C values were calculated as follows: Non-HDL-C (mg/dL) = TC – HDL-C.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.41" lower_limit="-28.37" upper_limit="-22.45"/>
                    <measurement group_id="O2" value="1.14" lower_limit="-2.63" upper_limit="4.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-26.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.35</ci_lower_limit>
            <ci_upper_limit>-22.75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in TG at Week 2</title>
        <description>Serum TG levels measured using enzymatic methods at baseline and after 2 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in TG at Week 2</title>
          <description>Serum TG levels measured using enzymatic methods at baseline and after 2 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.90" lower_limit="-10.66" upper_limit="3.37"/>
                    <measurement group_id="O2" value="5.83" lower_limit="-4.76" upper_limit="17.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.137</p_value>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-9.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.73</ci_lower_limit>
            <ci_upper_limit>3.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in TG at Week 4</title>
        <description>Serum TG levels measured using enzymatic methods at baseline and after 4 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in TG at Week 4</title>
          <description>Serum TG levels measured using enzymatic methods at baseline and after 4 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.54" lower_limit="-11.05" upper_limit="0.31"/>
                    <measurement group_id="O2" value="9.65" lower_limit="0.60" upper_limit="19.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-15.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.05</ci_lower_limit>
            <ci_upper_limit>-4.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in TG at Week 8</title>
        <description>Serum TG levels measured using enzymatic methods at baseline and after 8 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in TG at Week 8</title>
          <description>Serum TG levels measured using enzymatic methods at baseline and after 8 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.99" lower_limit="-16.28" upper_limit="-3.21"/>
                    <measurement group_id="O2" value="-1.38" lower_limit="-11.02" upper_limit="9.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.149</p_value>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-8.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.44</ci_lower_limit>
            <ci_upper_limit>3.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Apolipoprotein A-I (Apo A-I) at Week 12</title>
        <description>Serum Apo A-I levels measured at baseline and after 12 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Apolipoprotein A-I (Apo A-I) at Week 12</title>
          <description>Serum Apo A-I levels measured at baseline and after 12 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" lower_limit="-1.86" upper_limit="5.46"/>
                    <measurement group_id="O2" value="3.71" lower_limit="-0.87" upper_limit="8.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.373</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-1.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.15</ci_lower_limit>
            <ci_upper_limit>2.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in TC:HDL-C Ratio at Week 2</title>
        <description>Serum TC:HDL-C Ratio calculated at baseline and after 2 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in TC:HDL-C Ratio at Week 2</title>
          <description>Serum TC:HDL-C Ratio calculated at baseline and after 2 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.21" lower_limit="-21.08" upper_limit="-13.34"/>
                    <measurement group_id="O2" value="2.56" lower_limit="-2.37" upper_limit="7.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in Least-squares mean</param_type>
            <param_value>-19.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.70</ci_lower_limit>
            <ci_upper_limit>-14.82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in TC:HDL-C Ratio at Week 4</title>
        <description>Serum TC:HDL-C Ratio calculated at baseline and after 4 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in TC:HDL-C Ratio at Week 4</title>
          <description>Serum TC:HDL-C Ratio calculated at baseline and after 4 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.36" lower_limit="-23.16" upper_limit="-15.56"/>
                    <measurement group_id="O2" value="1.48" lower_limit="-3.30" upper_limit="6.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-20.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.59</ci_lower_limit>
            <ci_upper_limit>-16.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in TC:HDL-C Ratio at Week 8</title>
        <description>Serum TC:HDL-C Ratio calculated at baseline and after 8 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in TC:HDL-C Ratio at Week 8</title>
          <description>Serum TC:HDL-C Ratio calculated at baseline and after 8 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.07" lower_limit="-24.20" upper_limit="-15.94"/>
                    <measurement group_id="O2" value="3.41" lower_limit="-1.87" upper_limit="8.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-23.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.00</ci_lower_limit>
            <ci_upper_limit>-17.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in TC:HDL-C Ratio at Week 12</title>
        <description>Serum TC:HDL-C Ratio calculated at baseline and after 12 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in TC:HDL-C Ratio at Week 12</title>
          <description>Serum TC:HDL-C Ratio calculated at baseline and after 12 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.09" lower_limit="-24.98" upper_limit="-17.19"/>
                    <measurement group_id="O2" value="1.20" lower_limit="-3.70" upper_limit="6.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-22.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.25</ci_lower_limit>
            <ci_upper_limit>-17.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 2</title>
        <description>Serum LDL-C:HDL-C Ratio calculated at baseline and after 2 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 2</title>
          <description>Serum LDL-C:HDL-C Ratio calculated at baseline and after 2 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.35" lower_limit="-27.69" upper_limit="-19.01"/>
                    <measurement group_id="O2" value="1.15" lower_limit="-4.35" upper_limit="6.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-24.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.88</ci_lower_limit>
            <ci_upper_limit>-19.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 4</title>
        <description>Serum LDL-C:HDL-C Ratio calculated at baseline and after 4 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 4</title>
          <description>Serum LDL-C:HDL-C Ratio calculated at baseline and after 4 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.72" lower_limit="-30.12" upper_limit="-21.33"/>
                    <measurement group_id="O2" value="-0.57" lower_limit="-6.14" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-25.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.69</ci_lower_limit>
            <ci_upper_limit>-19.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 8</title>
        <description>Serum LDL-C:HDL-C Ratio calculated at baseline and after 8 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 8</title>
          <description>Serum LDL-C:HDL-C Ratio calculated at baseline and after 8 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.43" lower_limit="-31.21" upper_limit="-21.66"/>
                    <measurement group_id="O2" value="2.87" lower_limit="-3.28" upper_limit="9.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-29.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.71</ci_lower_limit>
            <ci_upper_limit>-22.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 12</title>
        <description>Serum LDL-C:HDL-C Ratio calculated at baseline and after 12 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 12</title>
          <description>Serum LDL-C:HDL-C Ratio calculated at baseline and after 12 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.01" lower_limit="-32.65" upper_limit="-23.36"/>
                    <measurement group_id="O2" value="0.34" lower_limit="-5.57" upper_limit="6.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-28.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.41</ci_lower_limit>
            <ci_upper_limit>-22.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Apo B:Apo A-I Ratio at Week 12</title>
        <description>Serum Apo B:Apo A-I Ratio calculated at baseline and after 12 weeks of study drug administration</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Apo B:Apo A-I Ratio at Week 12</title>
          <description>Serum Apo B:Apo A-I Ratio calculated at baseline and after 12 weeks of study drug administration</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.16" lower_limit="-26.13" upper_limit="-18.19"/>
                    <measurement group_id="O2" value="-2.87" lower_limit="-7.84" upper_limit="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-19.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.87</ci_lower_limit>
            <ci_upper_limit>-14.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 4</title>
        <description>Plasma hs-CRP measured at baseline and after 4 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 4</title>
          <description>Plasma hs-CRP measured at baseline and after 4 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00" lower_limit="-15.65" upper_limit="43.45"/>
                    <measurement group_id="O2" value="56.11" lower_limit="7.68" upper_limit="126.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.116</p_value>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-46.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-108.14</ci_lower_limit>
            <ci_upper_limit>15.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 12</title>
        <description>Plasma hs-CRP measured at baseline and after 12 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 12</title>
          <description>Plasma hs-CRP measured at baseline and after 12 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.35" lower_limit="-13.47" upper_limit="38.19"/>
                    <measurement group_id="O2" value="-7.92" lower_limit="-33.48" upper_limit="27.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.382</p_value>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>17.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.46</ci_lower_limit>
            <ci_upper_limit>55.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Sitosterol at Week 2</title>
        <description>Plasma sitosterol measured at baseline and after 2 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Sitosterol at Week 2</title>
          <description>Plasma sitosterol measured at baseline and after 2 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.20" lower_limit="-54.65" upper_limit="-45.76"/>
                    <measurement group_id="O2" value="-0.59" lower_limit="-6.26" upper_limit="5.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-49.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-55.36</ci_lower_limit>
            <ci_upper_limit>-43.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Sitosterol at Week 4</title>
        <description>Plasma sitosterol measured at baseline and after 4 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Sitosterol at Week 4</title>
          <description>Plasma sitosterol measured at baseline and after 4 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-58.82" lower_limit="-63.04" upper_limit="-54.61"/>
                    <measurement group_id="O2" value="-0.30" lower_limit="-5.52" upper_limit="4.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-58.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-63.67</ci_lower_limit>
            <ci_upper_limit>-53.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Sitosterol at Week 8</title>
        <description>Plasma sitosterol measured at baseline and after 8 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Sitosterol at Week 8</title>
          <description>Plasma sitosterol measured at baseline and after 8 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-61.59" lower_limit="-66.39" upper_limit="-56.78"/>
                    <measurement group_id="O2" value="-0.57" lower_limit="-6.69" upper_limit="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-61.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-67.51</ci_lower_limit>
            <ci_upper_limit>-54.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Sitosterol at Week 12</title>
        <description>Plasma sitosterol measured at baseline and after 12 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Sitosterol at Week 12</title>
          <description>Plasma sitosterol measured at baseline and after 12 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-60.65" lower_limit="-67.39" upper_limit="-53.92"/>
                    <measurement group_id="O2" value="2.09" lower_limit="-7.01" upper_limit="11.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-62.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-73.22</ci_lower_limit>
            <ci_upper_limit>-52.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Campesterol at Week 2</title>
        <description>Plasma campesterol measured at baseline and after 2 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Campesterol at Week 2</title>
          <description>Plasma campesterol measured at baseline and after 2 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53.87" lower_limit="-57.99" upper_limit="-49.74"/>
                    <measurement group_id="O2" value="-4.38" lower_limit="-9.66" upper_limit="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-49.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.83</ci_lower_limit>
            <ci_upper_limit>-44.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Campesterol at Week 4</title>
        <description>Plasma campesterol measured at baseline and after 4 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Campesterol at Week 4</title>
          <description>Plasma campesterol measured at baseline and after 4 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-62.27" lower_limit="-66.21" upper_limit="-58.32"/>
                    <measurement group_id="O2" value="-4.28" lower_limit="-9.20" upper_limit="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-57.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-62.87</ci_lower_limit>
            <ci_upper_limit>-53.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Campesterol at Week 8</title>
        <description>Plasma campesterol measured at baseline and after 8 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Campesterol at Week 8</title>
          <description>Plasma campesterol measured at baseline and after 8 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-66.79" lower_limit="-71.21" upper_limit="-62.37"/>
                    <measurement group_id="O2" value="-4.19" lower_limit="-9.83" upper_limit="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-62.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-68.54</ci_lower_limit>
            <ci_upper_limit>-56.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Campesterol at Week 12</title>
        <description>Plasma campesterol measured at baseline and after 12 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Campesterol at Week 12</title>
          <description>Plasma campesterol measured at baseline and after 12 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-67.59" lower_limit="-73.68" upper_limit="-61.50"/>
                    <measurement group_id="O2" value="-2.92" lower_limit="-11.15" upper_limit="5.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-64.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-74.11</ci_lower_limit>
            <ci_upper_limit>-55.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Cholestanol at Week 2</title>
        <description>Plasma cholestanol measured at baseline and after 2 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Cholestanol at Week 2</title>
          <description>Plasma cholestanol measured at baseline and after 2 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.44" lower_limit="-30.30" upper_limit="-20.59"/>
                    <measurement group_id="O2" value="-7.09" lower_limit="-13.29" upper_limit="-0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-18.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.70</ci_lower_limit>
            <ci_upper_limit>-11.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Cholestanol at Week 4</title>
        <description>Plasma cholestanol measured at baseline and after 4 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Cholestanol at Week 4</title>
          <description>Plasma cholestanol measured at baseline and after 4 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.40" lower_limit="-31.95" upper_limit="-22.85"/>
                    <measurement group_id="O2" value="-1.79" lower_limit="-7.42" upper_limit="3.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-25.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.20</ci_lower_limit>
            <ci_upper_limit>-20.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Cholestanol at Week 8</title>
        <description>Plasma cholestanol measured at baseline and after 8 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Cholestanol at Week 8</title>
          <description>Plasma cholestanol measured at baseline and after 8 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.19" lower_limit="-33.98" upper_limit="-24.39"/>
                    <measurement group_id="O2" value="-0.44" lower_limit="-6.44" upper_limit="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-28.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.89</ci_lower_limit>
            <ci_upper_limit>-22.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Cholestanol at Week 12</title>
        <description>Plasma cholestanol measured at baseline and after 12 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Cholestanol at Week 12</title>
          <description>Plasma cholestanol measured at baseline and after 12 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.71" lower_limit="-34.44" upper_limit="-22.99"/>
                    <measurement group_id="O2" value="3.42" lower_limit="-4.07" upper_limit="10.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>-32.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.38</ci_lower_limit>
            <ci_upper_limit>-23.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Lathosterol at Week 2</title>
        <description>Plasma lathosterol measured at baseline and after 2 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Lathosterol at Week 2</title>
          <description>Plasma lathosterol measured at baseline and after 2 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.07" lower_limit="24.68" upper_limit="43.45"/>
                    <measurement group_id="O2" value="14.06" lower_limit="2.22" upper_limit="25.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>20.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.10</ci_lower_limit>
            <ci_upper_limit>31.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Lathosterol at Week 4</title>
        <description>Plasma lathosterol measured at baseline and after 4 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Lathosterol at Week 4</title>
          <description>Plasma lathosterol measured at baseline and after 4 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.02" lower_limit="23.44" upper_limit="42.60"/>
                    <measurement group_id="O2" value="6.73" lower_limit="-5.27" upper_limit="18.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>26.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.99</ci_lower_limit>
            <ci_upper_limit>38.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Lathosterol at Week 8</title>
        <description>Plasma lathosterol measured at baseline and after 8 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Lathosterol at Week 8</title>
          <description>Plasma lathosterol measured at baseline and after 8 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.87" lower_limit="26.14" upper_limit="45.61"/>
                    <measurement group_id="O2" value="-0.82" lower_limit="-12.99" upper_limit="11.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>36.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>24.12</ci_lower_limit>
            <ci_upper_limit>49.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Lathosterol at Week 12</title>
        <description>Plasma lathosterol measured at baseline and after 12 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe</title>
            <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Lathosterol at Week 12</title>
          <description>Plasma lathosterol measured at baseline and after 12 weeks of study drug administration.</description>
          <population>Full Analysis Set (FAS) population defined as all randomized participants who took at least one dose of study medication and had a baseline value and at least one valid post-baseline evaluation.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.62" lower_limit="26.46" upper_limit="46.78"/>
                    <measurement group_id="O2" value="12.57" lower_limit="-0.36" upper_limit="25.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least-squares means</param_type>
            <param_value>24.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.43</ci_lower_limit>
            <ci_upper_limit>37.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety analysis was performed on the All-Patients-as-Treated (APaT) Population defined as all randomized patients who received at least one dose of double-blind study therapy.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ezetimibe</title>
          <description>Ezetimibe 10-mg tablet once daily for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy congenital</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="92"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="92"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator agreed not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The investigator further agreed to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

